Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $11.02 billion. The enterprise value is $8.86 billion.
Important Dates
The last earnings date was Tuesday, November 5, 2024, after market close.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 124.64 million shares outstanding. The number of shares has increased by 24.70% in one year.
| Current Share Class | 124.64M |
| Shares Outstanding | 124.64M |
| Shares Change (YoY) | +24.70% |
| Shares Change (QoQ) | +5.49% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 104.03% |
| Float | 114.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.22 |
| P/TBV Ratio | 3.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.88, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.88 |
| Quick Ratio | 17.76 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -21.06% and return on invested capital (ROIC) is -15.53%.
| Return on Equity (ROE) | -21.06% |
| Return on Assets (ROA) | -14.93% |
| Return on Capital (ROIC) | -15.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.00M |
| Employee Count | 254 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.93% in the last 52 weeks. The beta is 1.01, so Vaxcyte's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +71.93% |
| 50-Day Moving Average | 108.44 |
| 200-Day Moving Average | 83.14 |
| Relative Strength Index (RSI) | 29.10 |
| Average Volume (20 Days) | 1,610,593 |
Short Selling Information
The latest short interest is 8.93 million, so 7.16% of the outstanding shares have been sold short.
| Short Interest | 8.93M |
| Short Previous Month | 9.34M |
| Short % of Shares Out | 7.16% |
| Short % of Float | 7.76% |
| Short Ratio (days to cover) | 12.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | -75.00M |
| Operating Income | -604.05M |
| Pretax Income | -497.19M |
| Net Income | -507.65M |
| EBITDA | -599.03M |
| EBIT | -604.05M |
| Earnings Per Share (EPS) | -$4.46 |
Full Income StatementBalance Sheet
The company has $2.18 billion in cash and $27.96 million in debt, giving a net cash position of $2.15 billion or $17.27 per share.
| Cash & Cash Equivalents | 2.18B |
| Total Debt | 27.96M |
| Net Cash | 2.15B |
| Net Cash Per Share | $17.27 |
| Equity (Book Value) | 3.42B |
| Book Value Per Share | 27.47 |
| Working Capital | 2.09B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$470.04 million and capital expenditures -$146.20 million, giving a free cash flow of -$616.24 million.
| Operating Cash Flow | -470.04M |
| Capital Expenditures | -146.20M |
| Free Cash Flow | -616.24M |
| FCF Per Share | -$4.94 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |